Multicentre, randomised, double blind, placebo controlled study on long-term treatment with Sulodexide for prevention of recurrent DVT in patients with venous thromboembolism.

Trial Profile

Multicentre, randomised, double blind, placebo controlled study on long-term treatment with Sulodexide for prevention of recurrent DVT in patients with venous thromboembolism.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Sulodexide (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms SURVET
  • Sponsors Alfa Wassermann SpA
  • Most Recent Events

    • 25 Sep 2015 Primary endpoint has been met. (Confirmed recurrence of venous thromboembolism) according to the results published in the Circulation.
    • 25 Sep 2015 Results published in the Circulation.
    • 12 Sep 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top